公司資料
Apellis Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- APLS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
41.03 USD (-0.07%)
收盤價
最後更新: 2026年5月13日
5.25B USD
市值
股價為何變動
Current closing-price context is not available for APLS.
公司概覽
Complement C3 Biology
Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases.
SYFOVRE
SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for geographic atrophy secondary to age-related macular degeneration. Apellis retains worldwide ophthalmology rights and is developing a prefilled-syringe presentation.
EMPAVELI
EMPAVELI, or systemic pegcetacoplan, is approved in the United States for paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Sobi commercializes systemic pegcetacoplan outside the United States.
Rare-Kidney Expansion
Pivotal studies are evaluating EMPAVELI in focal segmental glomerulosclerosis and delayed graft function. These programs extend systemic C3 inhibition into additional kidney diseases with substantial complement involvement.
Next-Generation Pipeline
APL-3007 is being combined with SYFOVRE in Phase 2 to achieve broader complement blockade in the retina and choroid. APL-90992 is a preclinical base-editing program intended to create a one-time treatment targeting the neonatal Fc receptor.
未來催化劑
- Regulatory submission for the SYFOVRE prefilled syringe planned in the first half of 2026.
- IND submission for APL-90992 planned in the second half of 2026.
- Topline Phase 2 data for SYFOVRE plus APL-3007 expected in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。